Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
Phase 3
Completed
- Conditions
- Prostate Cancer
- Interventions
- Drug: Androgen Deprivation Therapy (ADT)
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 522
- Registration Number
- NCT00242567
- Locations
- 🇹🇭
Novartis Investigative Site, Songkhla, Thailand
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
Phase 4
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT00242554
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2012-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT00242541
- Locations
- 🇲🇽
Novartis Investigative Site, Mexico City, Mexico
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
Phase 3
Completed
- Conditions
- Macular DegenerationChoroidal Neovascularization
- Interventions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT00242580
- Locations
- 🇺🇸
Novartis Investigational Site, Austin, Texas, United States
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 270
- Registration Number
- NCT00241020
Letrozole in the Treatment of Severe and Recurrent Endometriosis
Phase 2
Completed
- Conditions
- Severe and Recurrent Endometriosis
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2012-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00240942
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
Phase 4
Terminated
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT00241046
Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 148
- Registration Number
- NCT00241111
Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients
Phase 3
Completed
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 684
- Registration Number
- NCT00239863
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
Phase 2
Completed
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 255
- Registration Number
- NCT00239798
© Copyright 2025. All Rights Reserved by MedPath